Tumour histology | Paxillin FISH | EGFR exon 19 | EGFR exon 21 | KRAS codons 12/13 |
Adenocarcinoma (1.5 cm), solid and acinar types, with focal signet ring features | Amplification | WT | WT | WT |
Adenocarcinoma with BAC pattern* | Amplification | WT | WT | Mutation |
Adenocarcinoma (1.6 cm) | Diploid | WT | WT | WT |
Adenocarcinoma (0.5 cm), acinar type | Diploid | WT | WT | WT |
Large cell carcinoma (1.7 cm) | Diploid | WT | WT | WT |
Squamous cell carcinoma (3.0 cm) | Diploid | WT | WT | NA |
Focal squamous metaplasia with dysplasia | Diploid | WT | WT | WT |
High-grade squamous cell carcinoma (3.7 cm) | Diploid | WT | WT | WT |
Adenosquamous carcinoma (1.2 cm) | Diploid | WT | WT | WT |
Adenocarinoma (3.5 cm) with sarcomatoid changes | Diploid | WT | WT | NA |
Adenosquamous carcinoma (1.2 cm) | Diploid | WT | WT | WT |
↵* Paxillin overexpression confirmed with immunohistochemistry.
BAC, bronchioloalveolar carcinoma; FISH, fluorescence in situ hybridisation; NA, KRAS PCR amplification failed; WT, wild-type.